• Disease Overview
  • Synonyms
  • Signs & Symptoms
  • Causes
  • Affected Populations
  • Disorders with Similar Symptoms
  • Diagnosis
  • Standard Therapies
  • Clinical Trials and Studies
  • References
  • Programs & Resources
  • Complete Report
Select language / seleccionar idioma:

KIF1A-Related Disorder


Last updated: 09/29/2023
Years published: 2019, 2023


NORD gratefully acknowledges Lia Boyle, MD, PhD, Columbia University Vagelos College of Physicians & Surgeons; Wendy Chung, MD, PhD, Clinical and Molecular Geneticist, Kennedy Family Professor of Pediatrics and Medicine, Columbia University Medical Center; and KIF1A.org, for assistance in the preparation of this report.

Disease Overview


KIF1A-related disorder is a group of genetic disorders caused by one or more variations (pathogenic variants or mutations) in the KIF1A gene. Researchers have determined that different variations of this gene have been associated with different signs and symptoms, progression and severity of disease. Although different variations lead to many of the same signs and symptoms, the specific symptoms that develop, the progression of the symptoms and the overall severity can vary greatly. This is true for people in different families with the same genetic variation and members within the same family with the same variation in the KIF1A gene. The differences are based, in part, on where in the gene the variation occurs and the type of variation that occurs. KIF1A-related disorder can be inherited as an autosomal dominant condition or due to a single new (de novo) variant and, in other families, can be inherited in an autosomal recessive pattern. KIF1A-related disorder can best be thought of as a spectrum of disease that can range from mild symptoms to severe and life-threatening. Treatment for these disorders is focused on treatment of symptoms.

Originally, changes in the KIF1A gene were thought to lead to three different disorders: nonsyndromic intellectual disability 9 (MRD9), currently known as NESCAV syndrome, hereditary sensory neuropathy type IIC (HSNIIC) and hereditary spastic paraplegia 30 (SPG30). Some affected individuals may have symptoms and inheritance patterns that fit neatly into these categories, but others do not.

  • Next section >
  • < Previous section
  • Next section >


  • KIF1A-associated neurological disorder (KAND)
  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Signs & Symptoms

The signs and symptoms of KIF1A-related disorder can vary greatly from one person to another depending on the specific variation in the gene that is present, the inheritance pattern and other factors. Much about KIF1A-related disorder is not fully understood. Several factors including the small number of identified patients prevent physicians from developing a complete picture of associated symptoms and prognosis. Therefore, it is important to note that affected individuals most likely will not have all of the symptoms discussed below and that every person is unique. Parents and patients should talk to their physician and medical team about their specific situation, associated symptoms and overall prognosis.

Some affected individuals have an autosomal dominant form of the disorder that has been associated with a variety of symptoms. These symptoms include intellectual disability, delays in reaching developmental milestones (developmental delays) and diminished muscle tone (hypotonia). Additional symptoms include exaggerated reflexes (hyperreflexia) and, as infants or children age, increased muscle tone (hypertonia). Eventually, affected children may develop spastic paraplegia, a condition in which people have difficulty walking due to muscle weakness and muscle tightness (spasticity) in the legs. Spastic paraplegia can become progressively worse, significantly affecting the ability walk and get around.

Spastic paraplegia is classified as “uncomplicated” or “pure” when symptoms are confined to leg weakness and tightness. Spastic paraplegia is classified as “complicated” when leg weakness and tightness (spasticity) are accompanied by other neurologic disturbances. Some individuals eventually develop contractures. A contracture is a condition in which a joint becomes permanently fixed in a bent or straightened position, completely or partially restricting the movement of the affected joint.

Some affected individuals have optic nerve atrophy, which is degeneration of the main nerve that carries nerve impulses from the eyes to the brain. Sometimes, the field of vision can be reduced. Some affected individuals experience progressive deterioration of the nerve cells of cerebellum (cerebellar atrophy) and other parts of the brain, which can cause problem with balance and coordination, seizures, and brain function generally. Peripheral neuropathy is a condition that occurs when nerves that carry messages to and from the brain and spinal cord to the rest of the body are damaged. Those affected may experience tingling, burning, numbness, and stabbing pain in the affected extremities.

Other symptoms that have been reported include poor coordination (ataxia), rapid, involuntary eye movements (nystagmus), crossed eyes (strabismus), drooping of the upper eyelid (ptosis), weakness or paralysis of half of the facial muscles (facial diplegia), clumsiness when trying to use their hands to manipulate or hold objects and tremors that occur when attempting to make deliberate actions (intention tremors). A variety of different seizure types have also been described and seizures during sleep can be a particular problem. Some individuals have abnormal electrical activity in the brain that is not a seizure but is not normal. Some individuals have developed abnormal curvature of the spine (scoliosis). Some infants have microcephaly, a condition in which the head is smaller than would otherwise be expected based on age and sex. Some infants and children experience backflow or regurgitation of the contents of the stomach into the esophagus (gastroesophageal reflux). Some males have had small testes or penis, or there is failure of the testes to descend into the scrotum (cryptorchidism).

Genetic variants in KIF1A have also been associated with amyotrophic lateral sclerosis (ALS).

Individuals with recessive forms of KIF1A-related disorder may have symptoms that fit neatly into the categories described or may have symptoms that look more like the autosomal dominant form of the condition described above.

Some individuals with variations in the KIF1A gene develop a form of hereditary sensory and autonomic neuropathy, specifically type IIC. Hereditary sensory neuropathies are a group of rare neurological disorders characterized by degeneration of the nervous system that frequently progresses to loss of feeling, especially in the hands and feet. Symptoms usually start with inflamed fingers or toes, especially around the nails. Numbness and tingling sensations in the hands and feet may also occur. Eventually, affected individuals lose feeling (sensation) in the hands and feet. This sensory loss is due to abnormal functioning of the sensory nerves that control responses to pain and temperature and may also affect the autonomic nervous system that controls other involuntary or automatic body processes. Chronic infection of the affected areas is common and worsens as ulcers form on the fingers or the soles of the hands and feet. NORD has a separate report on hereditary sensory and autonomic neuropathy type II. For more information, choose the exact disorder name as your search term in the Rare Disease Database.

Some individuals with variations in the KIF1A gene develop a form of hereditary spastic paraplegia, specifically hereditary spastic paraplegia type 30, or autosomal recessive spastic paraplegia 30, or SP30. The hereditary spastic paraplegias (HSP) are a large group of inherited neurologic disorders that share the primary symptom of difficulty walking due to muscle weakness and muscle tightness (spasticity) in the legs. There are more than 80 different genetic types of HSP. There may be significant variation in the severity of leg weakness (varying from none to marked), the degree of spasticity (varying from minimal to severe) and the occurrence of other neurologic symptoms between different genetic types of HSP; as well differences in the nature and severity of symptoms between individuals who have exactly the same genetic type of HSP. NORD has a separate report on hereditary spastic paraplegia. For more information, choose “hereditary spastic paraplegia” as your search term in the Rare Disease Database.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


KIF1A-related disorders are caused by changes (mutations or variants) in the KIF1A gene. Genes provide instructions for creating proteins that play a critical role in many functions of the body. When a variation in a gene occurs, the protein product may be faulty, inefficient, absent or overproduced. Depending upon the functions of the particular protein, this can affect many organ systems of the body, including the brain.

The KIF1A gene produces a protein that is expressed solely in the brain and nerves. The protein has a role in transporting or carrying substances within cells (intracellular transport), specifically these protein helps to transport substances through a tubular structure in nerve fibers (axonal microtubules). Some studies suggest that this protein is essential for the function and survival of sensory nerve cells (neurons). Sensory neurons are the nerves cells that respond to stimuli like pain or temperature.

Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease, while recessive disorders occur when an individual inherits two copies of an abnormal gene, one from each parent. In dominant disorders, the abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. Some people with a KIF1A-related disorder have a variation in the KIF1A gene have a new (sporadic or de novo) mutation, which means that in nearly all families the gene mutation has occurred at the time of the formation of the egg or sperm for that child only, and no other family member will be affected. The disorder is usually not inherited from or “carried” by a healthy parent. The genetic variant can then be passed on by the affected person in an autosomal dominant pattern. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.

At least two distinct disorders are associated with variations in the KIF1A gene that are inherited in an autosomal recessive pattern. These disorders are hereditary sensory and autonomic neuropathy IIC and hereditary spastic paraplegia 30. Disorders inherited in a recessive pattern occur when an individual inherits two variants in a gene for the same trait, one from each parent. If an individual receives one normal gene and one gene variant for the disease, the person will be a carrier for the disease, but usually will not show symptoms. The risk for two carrier parents to both pass the abnormal gene variant and, therefore, have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents is 25%. The risk is the same for males and females.

Some affected individuals are compound heterozygotes, which means that they have inherited two different autosomal recessive mutations that have the combined effect of causing disease.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Affected populations

KIF1A-related disorder is extremely rare. The number of people affected by these disorders is unknown. Rare disorders often go undiagnosed or misdiagnosed, making it extremely difficult to determine their true frequency in the general population. As of November 2022, according to KIF1A.org, there are approximately 500 people known to have a disease-causing variation in the KIF1A gene.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >


A diagnosis of a KIF1A-related disorder is suspected based upon the identification of characteristic symptoms, a detailed patient and family history, a thorough clinical evaluation, and a variety of specialized tests. A diagnosis is confirmed through molecular genetic testing on a blood sample, which can detect variants in the KIFA1 gene, but is available only as a diagnostic service at specialized laboratories.

Some individuals will have tests that cover a subset of genes related to the individual’s symptoms (panel testing) while others will have exome sequencing. Sometimes blood from the parents is requested for comparison as part of exome sequencing. Exome sequencing is a molecular genetic testing method that examines the genes in humans that contain instructions for creating proteins (protein-encoding genes). This is called the exome. Genetic sequencing can detect genetic variations in the KIF1A gene that are known to cause disease, or variations in other genes known to cause symptoms similar to KIF1A-related disorder.

Clinical Testing and Workup
Affected individuals may undergo additional tests to assess the extent of the disease. Two of the more common symptoms of the condition are problems with vision due to issues with the nerves of the eye (optic nerve atrophy) and seizures. Optic nerve atrophy can be difficult to detect so individuals may be referred to see an eye doctor specializing in neurological conditions that affect the eyes (neuro-ophthalmologist). Since seizures and abnormal brain activity during sleep are common, longer electroencephalograms (EEG) that last 24-48 hours may be recommended. An EEG records the brain’s electrical activity and can detect seizures that might not be obvious, as well as detect abnormal brain activity that is not a seizure.

Neurologic examination is important for individuals with the symptoms of a KIF1A-related disorder. Neurologic examination helps identify the specific features affecting a person. Laboratory tests, neurophysiologic testing, and neuroimaging; routine laboratory studies (such as blood counts, serum electrolytes and tests of kidney, liver, and endocrine functions); and analysis of cerebrospinal fluid (obtained by “spinal tap”) may be conducted to help exclude alternate and co-existing diagnoses.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Standard Therapies

The treatment of KIF1A-related disorder is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, physicians who specialize in the diagnosis and treatment of neurological disorders in children (pediatric neurologists), neurologists, physicians who specialize in the diagnosis and treatment of eye disorders (ophthalmologists), speech pathologists, physical therapists, and other healthcare professionals may need to systematically and comprehensively plan treatment.

Genetic counseling is recommended for affected individuals and their families. Psychosocial support for the entire family is essential as well.

There are no standardized treatment protocols or guidelines for affected individuals. Due to the rarity of the disease, there are no treatment trials that have been tested on a large group of patients. Various treatments have been reported in the medical literature as part of single case reports or small series of patients. Treatment trials will be very helpful to determine the long-term safety and effectiveness of specific medications and treatments for individuals with KIF1A-related disorder.

Following an initial diagnosis, a developmental assessment may be performed and appropriate occupational, physical, speech and feeding therapies be instituted. Periodic reassessments and adjustment of services should be provided with all children. Additional medical, social, and/or vocational services including specialized learning programs may be necessary.

Medications may be tried to treat seizures, spasticity neuropathy, and certain neurological aspects of KIF1A-related disorder. Orthopedic devies including braces, gait trainers, and other devices may help children walk. Additional treatment is symptomatic and supportive.

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >

Clinical Trials and Studies

Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll-free: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]

Some current clinical trials also are posted on the following page on the NORD website:

For information about clinical trials sponsored by private sources, contact:

For information about clinical trials conducted in Europe, contact:

  • < Previous section
  • Next section >
  • < Previous section
  • Next section >



Liao P, Yuan Y, Liu Z, et al. Association of variants in the KIF1A gene with amyotrophic lateral sclerosis. Transl Neurodegener. 2022 Oct 26;11(1):46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9597953/

Boyle L, Rao L, Kaur S, Fan X, Mebane C, Hamm L, Thornton A, Ahrendsen JT, Anderson MP, Christodolou J, Gennerich A, Shen Y, Chung WK. Genotype and defects in microtubule-based motility correlate with clinical severity in KIF1A-associated neurological disorder. HGG Adv. 2021 Apr 8;2(2):100026. doi: 10.1016/j.xhgg.2021.100026. Epub 2021 Jan 30. PMID: 33880452. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054982/

Kaur S, Van Bergen NJ, Verhey KJ, et al. Expansion of the phenotypic spectrum of de novo missense variants in kinesin family member 1A (KIF1A). Hum Mutat. 2020 Oct;41(10):1761-1774. doi: 10.1002/humu.24079. Epub 2020 Jul 22. PMID: 32652677.  https://onlinelibrary.wiley.com/doi/10.1002/humu.24079

Cheon CK, Lim SH, Kim YM, et al. Autosomal dominant transmission of complicated hereditary spastic paraplegia due to a dominant negative mutation of KIF1A, SPG30 gene. Sci Rep. 2017;7:12527. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624960/

Raffa L, Matton MP, Michaud J, et al. Optic nerve hypoplasia in a patient with a de novo KIF1A heterozygous mutation. Can J Ophthalmol. 2017;52:e169-e171. https://www.canadianjournalofophthalmology.ca/article/S0008-4182(16)30614-7/fulltext

Roda RH, Schindler AB, Blackstone C. Multigenerational family with dominant SPG30 hereditary spastic paraplegia. Ann Clin Transl Neurol. 2017;4:821-824. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682118/

Tomaselli PJ, Rossor AM, Horga A, et al. A de novo dominant mutation in KIF1A associated with axonal neuropathy, spasticity and autism spectrum disorder. J Peripher Nerv Syst. 2017;22:46-463. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763335/

Hotchkiss L, Donkervoort S, Leach ME, et al. Novel de novo mutations in KIF1A as a cause of hereditary spastic paraplegia with progressive central nervous system involvement. J Child Neurol. 2016;31:1114-1119. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030766/

Tanaka Y, Niwa S, Dong M, et al. The molecular motor KIF1A transports the TrkA neurotrophin receptor and is essential for sensory neuron survival and function. Neuron. 2016;90:1215-1229. https://www.ncbi.nlm.nih.gov/pubmed/27263974

Citterio A, Arnodli A, Panzeri E, et al. Variants in KIF1A gene in dominant and sporadic forms of hereditary spastic paraparesis. J Neurol. 2015;262:2684-2690. https://www.ncbi.nlm.nih.gov/pubmed/26410750

Esmaeeli Nieh S, Madou MR, Sirajuddin M, et al. De novo mutations in KIF1A cause progressive encephalopathy and brain atrophy. Ann Clin Transl Neurol. 2015;2:623-635. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479523/

Lee JR, Srour M, Kim D, et al. De novo mutations in the motor domain of the KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy. Hum Mutat. 2015;36:69-78. https://www.ncbi.nlm.nih.gov/pubmed/25265257

Ohba C, Haginoya K, Osaka H, et al. De novo KIF1A mutations cause intellectual deficit, cerebellar atrophy, lower limb spasticity and visual disturbance. J Hum Genet. 2015;60:739-742. https://www.ncbi.nlm.nih.gov/pubmed/26354034

Okamotor N, Miya F, Tsunoda T, et al. KIF1A mutation in a patient with progressive neurodegeneration. J Hum Genet. 2014;59:639-641. https://www.ncbi.nlm.nih.gov/pubmed/25253658

Hamdan FF, Gauthier J, Araki Y, et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsydromic intellectual disability. Am J Hum Genet. 2011;88:306-316. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059427/

McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:601255; Last Update: 01/11/2021. Available at: https://www.omim.org/entry/601255 Accessed Dec 15, 2022.

  • < Previous section
  • Next section >

Programs & Resources

RareCare® Assistance Programs

NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.

Additional Assistance Programs

MedicAlert Assistance Program

NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.

Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/

Rare Disease Educational Support Program

Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.

Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/

Rare Caregiver Respite Program

This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.

Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/

Patient Organizations

NORD Breakthrough Summit | Rare Disease Conference